193 related articles for article (PubMed ID: 32332043)
1. Pericardial relapse of multiple myeloma.
Jamison LS; Mo CC; Kwok M
BMJ Case Rep; 2020 Apr; 13(4):. PubMed ID: 32332043
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
Baertsch MA; Schlenzka J; Mai EK; Merz M; Hillengaß J; Raab MS; Hose D; Wuchter P; Ho AD; Jauch A; Hielscher T; Kunz C; Luntz S; Klein S; Schmidt-Wolf IG; Goerner M; Schmidt-Hieber M; Reimer P; Graeven U; Fenk R; Salwender H; Scheid C; Nogai A; Haenel M; Lindemann HW; Martin H; Noppeney R; Weisel K; Goldschmidt H
BMC Cancer; 2016 Apr; 16():290. PubMed ID: 27114074
[TBL] [Abstract][Full Text] [Related]
4. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
5. [Multiple myeloma with myelofibrosis at diagnosis and aggressive extramedullary relapse after autologous stem cell transplantation].
Kodama Y; Saburi M; Kawano K; Uraisami K; Takata H; Miyazaki Y; Wada J; Urabe S; Ohtsuka E
Rinsho Ketsueki; 2024; 65(1):1-6. PubMed ID: 38311382
[TBL] [Abstract][Full Text] [Related]
6. Management of Multiple Myeloma.
Kumar SK
J Natl Compr Canc Netw; 2018 May; 16(5S):624-627. PubMed ID: 29784741
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
8. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Sonneveld P; Avet-Loiseau H; Lonial S; Usmani S; Siegel D; Anderson KC; Chng WJ; Moreau P; Attal M; Kyle RA; Caers J; Hillengass J; San Miguel J; van de Donk NW; Einsele H; Bladé J; Durie BG; Goldschmidt H; Mateos MV; Palumbo A; Orlowski R
Blood; 2016 Jun; 127(24):2955-62. PubMed ID: 27002115
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419
[TBL] [Abstract][Full Text] [Related]
10. Coincident remission of ankylosing spondylitis after autologous stem cell transplantation for multiple myeloma.
Shaikh H; Bakalov V; Shaikh S; Khattab A; Sadashiv S
J Oncol Pharm Pract; 2021 Jan; 27(1):232-234. PubMed ID: 32493162
[TBL] [Abstract][Full Text] [Related]
11. [Successful treatment of relapse/refractory multiple myeloma with carfilzomib, lenalidomide, and dexamethasone combination therapy following allogeneic bone marrow transplantation].
Fuchida SI; Shimura K; Taminishi-Katsuragawa Y; Matsui-Maegawa S; Okano A; Hatsuse M; Murakami S; Shimazaki C
Rinsho Ketsueki; 2019; 60(10):1468-1470. PubMed ID: 31695009
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Rajkumar SV
Am J Hematol; 2013 Mar; 88(3):226-35. PubMed ID: 23440663
[TBL] [Abstract][Full Text] [Related]
14. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
Venner CP; Connors JM; Sutherland HJ; Shepherd JD; Hamata L; Mourad YA; Barnett MJ; Broady R; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Nitta J; Power MM; Toze CL; Smith CA; Song KW
Leuk Lymphoma; 2011 Jan; 52(1):34-41. PubMed ID: 21133716
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
17. [Rapidly progressive AL amyloidosis in a patient with relapsed multiple myeloma after achieving a complete response to tandem autologous PBSCT].
Yagi H; Ozaki S; Sekimoto E; Shibata H; Shigekiyo T; Satake N
Rinsho Ketsueki; 2013 Dec; 54(12):2171-6. PubMed ID: 24452148
[TBL] [Abstract][Full Text] [Related]
18. Disseminated adenovirus infection in a patient with relapsed refractory multiple myeloma undergoing autologous stem cell transplantation and pomalidomide/dexamethasone as salvage regimens.
Yasuda S; Najima Y; Konishi T; Yamada Y; Takezaki T; Kurosawa S; Sakaguchi M; Harada K; Yoshioka K; Igarashi A; Inamoto K; Toya T; Kobayashi T; Doki N; Kakihana K; Sakamaki H; Sekiya N; Ohashi K
J Infect Chemother; 2019 May; 25(5):371-375. PubMed ID: 30642772
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
[Next] [New Search]